[Comment] Co-medications and gut microbiome in NSCLC immunotherapy | ClinicLens
In a post-hoc analysis of the PACIFIC trial published in The Lancet Oncology, Leonardo Brunetti and colleagues1 found that baseline proton pump inhibitor and antibiotic use was associated with worse progression-free survival in patients with stage III non-small-cell lung cancer (
Medical Literature · Updated
← Back to articlesIf the embedded page does not load in your browser, open it directly.